SAN DIEGO, July 2, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (www.apricusbio.com) announced today that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at the JMP Securities Healthcare Conference, being held at The Peninsula in New York City. Apricus Biosciences' presentation will take place on July 12, 2012 at 12:00pm Eastern Time.
Dr. Damaj will provide a corporate update, including details related to the recently announced acquisition of Finesco, the French parent and holding company of Scomedica, a leading French pharmaceutical sales and marketing organization, and an overview of the Company's global regulatory and growth strategy. Apricus Bio intends to self-commercialize Vitaros®, its flagship product for the treatment of erectile dysfunction, in France, and will use the Scomedica sales force as a base for the Company's commercial operations in Europe.
About Vitaros®
Vitaros® is a topically delivered formulation of alprostadil combined with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT® delivery technology, for the treatment of erectile dysfunction ("ED"). When absorbed through the skin, alprostadil, a vasodilator, directly boosts blood flow, thereby causing an erection.
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based revenue-generating pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT® technology. Apricus Bio also recently announced ownership of Scomedica, a leading French healthcare contract sales and marketing organization, which the Company intends to use as a base for its commercial operations in Europe, and which will be used to launch Vitaros® for erectile dysfunction ("ED") as well as other marketed and pipeline products, in France and other territories.
Apricus Bio's current NexACT® pipeline includes Vitaros®, approved in Canada for the treatment of erectile dysfunction, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.
Apricus Bio currently markets Totect® (dexrazoxane HCl), the only drug approved in the US for the treatment of anthracycline extravasation and Granisol® (granisetron HCI) oral solution, the only FDA-approved, oral, ready-to-use liquid solution of granisetron. The Company also plans to market in the U.S. or certain other countries Aquoral™, an FDA-cleared, prescription-only spray for the treatment of Xerostomia (the medical term for dry mouth due to a lack of saliva) and NitroMist® (nitroglycerin sublingual spray), an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease (narrowing of the blood vessels that supply blood to the heart).
The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiary please visit http://www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to successfully integrate Finesco and Scomedica into the Company and further develop its products and product candidates, to have its products and product candidates such as Vitaros®, Femprox® and MycoVa™ receive patent protection and be approved by relevant regulatory authorities, to successfully commercialize such products as Totect®, Granisol®, Aquoral™ and NitroMist™ and NexACT® product candidates and drug delivery technology and to achieve its development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. The shares to be contributed by Apricus Biosciences have not been registered under the Securities Act of 1933, as amended, and are to be issued, subject to the satisfaction or waiver of the conditions to issuance, pursuant to exemptions from the registration provisions of such Act. The shares may not be re-offered or resold in the United States absent registration or an applicable exemption from registration requirements.